MarketInOut Stock Screener Log In | Sign Up

Erasca Inc

NASDAQ • Healthcare • Biotechnology • Quote as of 10/30/2026
Erasca Inc stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization5,019.09 mln
Float247 mln
Earnings Date11/11/2026

Piotroski F-Score

1 / 9
Very weak

Relative Strength

88 / 100
Strongly outperforming

Debt / Equity

0.12
Very low leverage

ROE

-79.75
Deeply negative

ROA

-66.19
Deeply negative

Business Description

Erasca is a San Diego-based company founded in 2018 that develops cancer treatments targeting a specific genetic pathway, known as RAS/MAPK, which drives the growth of many tumors. The company has several treatments in development, including therapies aimed at different mutations within this pathway, and works with a number of partners around the world to research, manufacture, and bring these treatments to market. Erasca's goal is to give patients with these hard-to-treat cancers more effective and precisely targeted options.

Key Fundamentals

EPS-0.95
ROE-79.75
ROIC-93.23
ROA-66.19
EBITDA, mln-284
EV / EBITDA-17.86
EV / EBIT-17.68

Quote Details

Last 14.35
Change -0.63 (-4.21%)
Open 14.66
Volume 3,691,140
Turnover 52,967,860
Average Volume 5,083,524

Financial Ratios

Leverage Ratio1.20
Current Ratio8.29
Price / Book13.14
Price / Tangible Book13.14
Debt / Equity0.12

Financial Strength

Piotroski F-Score 1 / 9
Short Ratio6.69
Short % of Float11.70

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week -0.28% 47 / 100   
1 Month -1.58% 50 / 100   
2 Months -23.95% 20 / 100   
6 Months 43.07% 95 / 100   
1 Year 508% 100 / 100   



Disclaimer - Privacy Policy - Terms of Service - Cookies - FAQ - Affiliates - Blog